Lantheus announces aPROMISE available on syngo.via platform

Lantheus Holdings announced that aPROMISE, its AI-enabled FDA-cleared medical device software, is now available on the syngo.via platform, from Siemens Healthineers, one of the leading workstation systems. Siemens Healthineers will be demonstrating the integrated solution at the upcoming annual Society of Nuclear Medicine and Molecular Imaging annual meeting in Toronto June 8-11, 2024. aPROMISE is a deep learning-enabled, FDA-cleared medical device software that provides quantitative total disease burden on PSMA PET/CT images, including those obtained using PYLARIFY PET/CT. In planned prospective and independent validation studies, aPROMISE has demonstrated rapid lesion detection and standardized quantitative tumor burden biomarkers in PSMA PET/CT imaging. Recent clinical studies have shown that total quantitative burden with aPROMISE supports patient selection for PSMA radioligand therapy and automates monitoring response over time.